AI brief of an SEC Form 8-K · COMPASS Pathways plc (CMPS)

Compass Pathways Q2 net loss widens to $253.8 million on $205.6 million warrant charge

Mixed Impact 4 of 5 earnings Written later

Compass Pathways reported a second-quarter 2026 net loss of $253.8 million, or $1.88 per share, up from $38.4 million, or $0.41 per share, a year earlier. The filing attributes the increase mainly to a non-cash $205.6 million loss from fair value changes in warrants, which move with the share price, while operating expenses were $52.4 million. The company says it expects to submit its final NDA for COMP360 in Q4 2026 and launch in the first half of 2027, subject to FDA approval and DEA rescheduling.

Key points

  • Q2 2026 net loss was $253.8 million ($1.88 per share), versus $38.4 million ($0.41 per share) in Q2 2025; the warrant fair value change was a $205.6 million loss.
  • Research and development expenses were $29.2 million, down from $30.3 million; general and administrative expenses rose to $23.2 million from $12.6 million, tied to commercial preparedness.
  • Cash and cash equivalents were $433.3 million at June 30, 2026, up from $149.6 million at December 31, 2025; debt was $50.7 million.
  • The company expects its cash position to fund operations and capital expenditures into 2028.

The filing

CompanyCOMPASS Pathways plc (CMPS)
Form8-K, current report
Filed with the SECAug 5, 2026, 6:31 AM ET
Accession number0001816590-26-000059

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.